Reply to: “Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?”

We highly appreciate the letter from A. Kumar, “Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?”1 on our recent article comparing stereotactic body radiation therapy (SBRT) with radiofrequency ablation (RFA) in Asian patients with h epatocellular carcinoma.2 We also thank him for his valuable comments regarding the role of adjuvant sorafenib following locoregional treatments.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research